Lenz: focused on an eye drop for age-related farsightedness

Lenz is well-financed to begin a pivotal study of a pupil-contracting eye drop addressing the largest market in ophthalmology: presbyopia, or age-related farsightedness.

Backed by Versant Ventures and RA Capital, newly rechristened Lenz Therapeutics Inc. will advance a formulation of AChE receptor agonist aceclidine that has been shown to improve near vision in a Phase II trial...